On August 29, 2019 GABA Therapeutics Inc. secured up to $15.5 million of Series A investment from Atai Life Science AG, which will take the GRX-917 program through Phase 2a.
ATAI Life Sciences AG is a global biotech platform and company builder, based in Berlin, London and New York, focused on curing mental health disorders. Clearly there are synergies between GABA Therapeutics and Atai Life Sciences, and both companies aim to collaborate and share resources where commercially viable.